A system of three transiting super-Earths in a cool dwarf star

We present the detection of three super-Earths transiting the cool star LP415-17, monitored by K2 mission in its 13th campaign. High resolution spectra obtained with HARPS-N/TNG showed that the star is a mid-late K dwarf. Using spectral synthesis models we infer its effective temperature, surface gravity and metallicity and subse- quently determined from evolutionary models a stellar radius of 0.58 R Sun. The planets have radii of 1.8, 2.6 and 1.9 R Earth and orbital periods of 6.34, 13.85 and 40.72 days. High resolution images discard any significant contamination by an intervening star in the line of sight. The orbit of the furthest planet has radius of 0.18 AU, close to the inner edge of the habitable zone. The system is suitable to improve our understanding of formation and dynamical evolution of super-Earth systems in the rocky - gaseous threshold, their atmospheres, internal structure, composition and interactions with host stars.Comment: Accepted for publication in MNRAS Letter

Gliese 49: activity evolution and detection of a super-Earth A HADES and CARMENES collaboration

Small planets around low-mass stars often show orbital periods in a range that corresponds to the temperate zones of their host stars which are therefore of prime interest for planet searches. Surface phenomena such as spots and faculae create periodic signals in radial velocities and in observational activity tracers in the same range, so they can mimic or hide true planetary signals. We aim to detect Doppler signals corresponding to planetary companions, determine their most probable orbital configurations, and understand the stellar activity and its impact on different datasets. We analyze 22 years of data of the M1.5V-type star Gl49 (BD+61 195) including HARPS-N and CARMENES spectrographs, complemented by APT2 and SNO photometry. Activity indices are calculated from the observed spectra, and all datasets are analyzed with periodograms and noise models. We investigate how the variation of stellar activity imprints on our datasets. We further test the origin of the signals and investigate phase shifts between the different sets. To search for the best-fit model we maximize the likelihood function in a Markov Chain Monte Carlo approach. As a result of this study, we are able to detect the super-Earth Gl49b with a minimum mass of 5.6 Ms. It orbits its host star with a period of 13.85d at a semi-major axis of 0.090 au and we calculate an equilibrium temperature of 350 K and a transit probability of 2.0%. The contribution from the spot-dominated host star to the different datasets is complex, and includes signals from the stellar rotation at 18.86d, evolutionary time-scales of activity phenomena at 40-80d, and a long-term variation of at least four years

Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry

Aims: This study aimed to assess age- and sex-related differences in management and 1-year risk for all-cause mortality and hospitalization in chronic heart failure (HF) patients. Methods and results: Of 16 354 patients included in the European Society of Cardiology Heart Failure Long-Term Registry, 9428 chronic HF patients were analysed [median age: 66 years; 28.5% women; mean left ventricular ejection fraction (LVEF) 37%]. Rates of use of guideline-directed medical therapy (GDMT) were high (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists: 85.7%, 88.7% and 58.8%, respectively). Crude GDMT utilization rates were lower in women than in men (all differences: P\ua0 64 0.001), and GDMT use became lower with ageing in both sexes, at baseline and at 1-year follow-up. Sex was not an independent predictor of GDMT prescription; however, age >75 years was a significant predictor of GDMT underutilization. Rates of all-cause mortality were lower in women than in men (7.1% vs. 8.7%; P\ua0=\ua00.015), as were rates of all-cause hospitalization (21.9% vs. 27.3%; P\ua075 years. Conclusions: There was a decline in GDMT use with advanced age in both sexes. Sex was not an independent predictor of GDMT or adverse outcomes. However, age >75 years independently predicted lower GDMT use and higher all-cause mortality in patients with LVEF 6445%

Examining the generalizability of research findings from archival data

This initiative examined systematically the extent to which a large set of archival research findings generalizes across contexts. We repeated the key analyses for 29 original strategic management effects in the same context (direct reproduction) as well as in 52 novel time periods and geographies; 45% of the reproductions returned results matching the original reports together with 55% of tests in different spans of years and 40% of tests in novel geographies. Some original findings were associated with multiple new tests. Reproducibility was the best predictor of generalizability-for the findings that proved directly reproducible, 84% emerged in other available time periods and 57% emerged in other geographies. Overall, only limited empirical evidence emerged for context sensitivity. In a forecasting survey, independent scientists were able to anticipate which effects would find support in tests in new samples

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

The role of c‐Kit/sGC signaling axis in vascular reactivity and hypertension

A. Introduction The receptor tyrosine kinase c‐Kit has been recently found to have a role in vasculoprotection. Genetic deletion of c‐Kit in smooth muscle cells increases aortic plaque accumulation and atherosclerosis burden in conditional hyperlipidemic mice. The present study tests whether a c‐Kit deficiency in mutant mice (KitW/Wv) leads to hypertension and impaired vascular relaxation. B. Methods Female and male c‐Kit mutant (KitW/Wv) and littermate (Kit+/+) control mice were commercially available (Jackson lab). Blood pressure was determined in conscious mice using the tail‐cuff method. The first‐order branch of mesenteric artery was mounted into a pressure myograph (DMT, Aarhus, Denmark) to assess endothelium‐dependent and ‐independent vasoreactivity under isobaric conditions. A search for differentially expressed genes between c‐Kit mutant and control SMC was performed using the Mouse MI‐Ready microarray (Ocean Ridge Biosciences). C. Results The deficiency of c‐Kit causes hypertension in mutant mice with respect to their control littermates (mean arterial pressure: 137.5 ± 5.0 vs. 113.06 ± 0.0, p=0.007). Acetylcholine (ACh) induced a concentration‐dependent relaxation of norepinephrine pre‐contracted vessels in both mutant and littermate mice. The Cox inhibitor indomethacin compromised ACh‐induced vasorelaxation only in c‐Kit deficient vessels but not in those from control mice, which highlighted the importance of endothelium‐derived prostaglandins for vasorelaxation in the absence of c‐Kit. Conversely, arteries of mutant mice were poor responders to a NO agonist (SNP). The secondary messenger, cyclic guanosine monophosphate, vasodilated both types of vessels in a similar manner, which indicated that defective NO activity in mutants was due to deficiencies in soluble guanylyl cyclase (sGC) or NO synthesis. A significant downregulation of smooth muscle sGC beta 1 subunit was further found in c‐Kit mutant cells using transcriptomics analysis. D. Conclusion These results suggest the existence of a novel c‐Kit/sGC signaling axis in SMC that may be relevant for the control of vascular reactivity and hypertension. This is from the Experimental Biology 2018 Meeting. There is no full text article associated with this published in The FASEB Journal